Table 4. Medication use at 12 months in the radiographic cohort.
| Negative (n=47) |
Single-positive (n=48) |
Double-positive (n=29) |
Triple-positive (n=97) |
p-value (triple-positive vs single-positive) |
|
|---|---|---|---|---|---|
| Methotrexate monotherapy | 12 (26%) | 25 (52%) | 8 (28%) | 31 (32%) | 0·020 |
| Sulfasalazine monotherapy | 3 (6%) | 4 (8%) | 2 (7%) | 12 (12%) | 0·46 |
| Hydroxychloroquine monotherapy | 4 (9%) | 3 (6%) | 0 | 4 (4%) | 0·58 |
| Any csDMARD monotherapy | 19 (40%) | 32 (67%) | 10 (34%) | 47 (48%) | 0·039 |
| Two csDMARDs | 11 (23%) | 14 (29%) | 8 (28%) | 27 (28%) | 0·86 |
| Three or more csDMARDs | 4 (9%) | 2 (4%) | 5 (17%) | 14 (14%) | 0·064 |
| Biologics | 0 | 0 | 0 | 2 (2%) | NA |
| Total taking csDMARDs or biologics at 12 months |
34 (72%) | 48 (100%) | 23 (79%) | 89 (92%) | NA |
| Oral prednisolone at 12 months | 10 (21%) | 12 (25%) | 10 (34%) | 33 (34%) | 0·27 |
| Any intramuscular or intra-articular steroid injection |
23 (49%) | 30 (63%) | 17 (59%) | 55 (57%) | 0·51 |
DMARD and oral prednisolone use is at the 1 year timepoint. Intramuscular or intra-articular steroid use is over the course of 1 year. The Egon Pearson N-1 corrected χ2 test for proportions was used to calculate the differences in proportions between triple-positive and single-positive patients. p-values less than 0·05 were considered significant. csDMARDs=conventional synthetic disease-modifying antirheumatic drugs.